Prevalence of Cognitive Impairment before Prostate Cancer Treatment
Cognitive impairment is common among patients with different types of cancer, even before cancer treatment, but no data were reported among patients with prostate cancer (PCa), who may be at high risk due to advanced age. This study aims to estimate the prevalence of cognitive impairment before PCa...
Gespeichert in:
| Veröffentlicht in: | Cancers 2022-03, Vol.14 (5), p.1355 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 5 |
| container_start_page | 1355 |
| container_title | Cancers |
| container_volume | 14 |
| creator | Araújo, Natália Costa, Adriana Lopes, Catarina Lopes-Conceição, Luisa Ferreira, Augusto Carneiro, Filipa Oliveira, Jorge Morais, Samantha Pacheco-Figueiredo, Luís Ruano, Luis Tedim Cruz, Vítor Pereira, Susana Lunet, Nuno |
| description | Cognitive impairment is common among patients with different types of cancer, even before cancer treatment, but no data were reported among patients with prostate cancer (PCa), who may be at high risk due to advanced age. This study aims to estimate the prevalence of cognitive impairment before PCa treatment. Between February 2018 and April 2021, the NEON-PC cohort recruited 605 patients with PCa proposed for treatment at the Portuguese Institute of Oncology of Porto. The Montreal Cognitive Assessment (MoCA) was used to assess cognitive performance. Participants with a MoCA < 1.5 standard deviations (SD) of age- and education-specific normative values were considered to have probable cognitive impairment (PCI) and were referred for a comprehensive neuropsychological assessment. Data from the population-based cohort EPIPorto (n = 351 men aged ≥40 years, evaluated in 2013−2015) were used for comparison. The prevalence of PCI was 17.4% in EPIPorto and 14.7% in NEON-PC (age- and education-adjusted odds ratio: 0.82, 95%CI: 0.58,1.18). Neuropsychological assessment was performed in 63 patients with PCa: 54.0% had cognitive impairment. These results suggest that the impact of PCa on cognitive performance could be negligible in the short term, contrary to what other studies have reported regarding other types of cancer. |
| doi_str_mv | 10.3390/cancers14051355 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8909497</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2638724847</sourcerecordid><originalsourceid>FETCH-LOGICAL-c448t-8130332900ef245b25398eaee7550bb22278a41e35fae04658e96997db24beca3</originalsourceid><addsrcrecordid>eNpdkc9LwzAUx4MobsydvUnBi5e6ND-biyDFH4OBO8xzSLvX2dE2M-kG_vembspcLi-Qz_u-78sXoesE31Oq8KQwbQHOJwzzhHJ-hoYESxILodj50X2Axt6vcTiUJlLISzSgnAgpBB2ibO5gZ2oISpEto8yu2qqrdhBNm42pXANtF-VQWgfR3FnfmQ6i7GdutHBguh64QhelqT2MD3WE3p-fFtlrPHt7mWaPs7hgLO3iNKHBAVEYQ0kYzwmnKgUDIDnHeU4IkalhCVBeGsBM8BSUUEouc8JyKAwdoYe97mabN7Aswmhnar1xVWPcl7am0v9f2upDr-xOpworpmQQuDsIOPu5Bd_ppvIF1LVpwW69JoKmkrCU9ejtCbq2W9eG9XpKioSy4H-EJnuqCH_jHZR_ZhKs-4z0SUah4-Z4hz_-NxH6Db3yjdM</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2637613425</pqid></control><display><type>article</type><title>Prevalence of Cognitive Impairment before Prostate Cancer Treatment</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Araújo, Natália ; Costa, Adriana ; Lopes, Catarina ; Lopes-Conceição, Luisa ; Ferreira, Augusto ; Carneiro, Filipa ; Oliveira, Jorge ; Morais, Samantha ; Pacheco-Figueiredo, Luís ; Ruano, Luis ; Tedim Cruz, Vítor ; Pereira, Susana ; Lunet, Nuno</creator><creatorcontrib>Araújo, Natália ; Costa, Adriana ; Lopes, Catarina ; Lopes-Conceição, Luisa ; Ferreira, Augusto ; Carneiro, Filipa ; Oliveira, Jorge ; Morais, Samantha ; Pacheco-Figueiredo, Luís ; Ruano, Luis ; Tedim Cruz, Vítor ; Pereira, Susana ; Lunet, Nuno</creatorcontrib><description>Cognitive impairment is common among patients with different types of cancer, even before cancer treatment, but no data were reported among patients with prostate cancer (PCa), who may be at high risk due to advanced age. This study aims to estimate the prevalence of cognitive impairment before PCa treatment. Between February 2018 and April 2021, the NEON-PC cohort recruited 605 patients with PCa proposed for treatment at the Portuguese Institute of Oncology of Porto. The Montreal Cognitive Assessment (MoCA) was used to assess cognitive performance. Participants with a MoCA < 1.5 standard deviations (SD) of age- and education-specific normative values were considered to have probable cognitive impairment (PCI) and were referred for a comprehensive neuropsychological assessment. Data from the population-based cohort EPIPorto (n = 351 men aged ≥40 years, evaluated in 2013−2015) were used for comparison. The prevalence of PCI was 17.4% in EPIPorto and 14.7% in NEON-PC (age- and education-adjusted odds ratio: 0.82, 95%CI: 0.58,1.18). Neuropsychological assessment was performed in 63 patients with PCa: 54.0% had cognitive impairment. These results suggest that the impact of PCa on cognitive performance could be negligible in the short term, contrary to what other studies have reported regarding other types of cancer.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers14051355</identifier><identifier>PMID: 35267663</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Autonomy ; Cancer therapies ; Cognitive ability ; COVID-19 ; Patients ; Prostate cancer ; Quality of life ; Testicular cancer ; Tumors</subject><ispartof>Cancers, 2022-03, Vol.14 (5), p.1355</ispartof><rights>2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 by the authors. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c448t-8130332900ef245b25398eaee7550bb22278a41e35fae04658e96997db24beca3</citedby><cites>FETCH-LOGICAL-c448t-8130332900ef245b25398eaee7550bb22278a41e35fae04658e96997db24beca3</cites><orcidid>0000-0002-0581-3663 ; 0000-0003-1870-1430 ; 0000-0002-0903-494X ; 0000-0002-5333-4771 ; 0000-0002-1652-8999 ; 0000-0003-0186-7223</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909497/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909497/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35267663$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Araújo, Natália</creatorcontrib><creatorcontrib>Costa, Adriana</creatorcontrib><creatorcontrib>Lopes, Catarina</creatorcontrib><creatorcontrib>Lopes-Conceição, Luisa</creatorcontrib><creatorcontrib>Ferreira, Augusto</creatorcontrib><creatorcontrib>Carneiro, Filipa</creatorcontrib><creatorcontrib>Oliveira, Jorge</creatorcontrib><creatorcontrib>Morais, Samantha</creatorcontrib><creatorcontrib>Pacheco-Figueiredo, Luís</creatorcontrib><creatorcontrib>Ruano, Luis</creatorcontrib><creatorcontrib>Tedim Cruz, Vítor</creatorcontrib><creatorcontrib>Pereira, Susana</creatorcontrib><creatorcontrib>Lunet, Nuno</creatorcontrib><title>Prevalence of Cognitive Impairment before Prostate Cancer Treatment</title><title>Cancers</title><addtitle>Cancers (Basel)</addtitle><description>Cognitive impairment is common among patients with different types of cancer, even before cancer treatment, but no data were reported among patients with prostate cancer (PCa), who may be at high risk due to advanced age. This study aims to estimate the prevalence of cognitive impairment before PCa treatment. Between February 2018 and April 2021, the NEON-PC cohort recruited 605 patients with PCa proposed for treatment at the Portuguese Institute of Oncology of Porto. The Montreal Cognitive Assessment (MoCA) was used to assess cognitive performance. Participants with a MoCA < 1.5 standard deviations (SD) of age- and education-specific normative values were considered to have probable cognitive impairment (PCI) and were referred for a comprehensive neuropsychological assessment. Data from the population-based cohort EPIPorto (n = 351 men aged ≥40 years, evaluated in 2013−2015) were used for comparison. The prevalence of PCI was 17.4% in EPIPorto and 14.7% in NEON-PC (age- and education-adjusted odds ratio: 0.82, 95%CI: 0.58,1.18). Neuropsychological assessment was performed in 63 patients with PCa: 54.0% had cognitive impairment. These results suggest that the impact of PCa on cognitive performance could be negligible in the short term, contrary to what other studies have reported regarding other types of cancer.</description><subject>Autonomy</subject><subject>Cancer therapies</subject><subject>Cognitive ability</subject><subject>COVID-19</subject><subject>Patients</subject><subject>Prostate cancer</subject><subject>Quality of life</subject><subject>Testicular cancer</subject><subject>Tumors</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkc9LwzAUx4MobsydvUnBi5e6ND-biyDFH4OBO8xzSLvX2dE2M-kG_vembspcLi-Qz_u-78sXoesE31Oq8KQwbQHOJwzzhHJ-hoYESxILodj50X2Axt6vcTiUJlLISzSgnAgpBB2ibO5gZ2oISpEto8yu2qqrdhBNm42pXANtF-VQWgfR3FnfmQ6i7GdutHBguh64QhelqT2MD3WE3p-fFtlrPHt7mWaPs7hgLO3iNKHBAVEYQ0kYzwmnKgUDIDnHeU4IkalhCVBeGsBM8BSUUEouc8JyKAwdoYe97mabN7Aswmhnar1xVWPcl7am0v9f2upDr-xOpworpmQQuDsIOPu5Bd_ppvIF1LVpwW69JoKmkrCU9ejtCbq2W9eG9XpKioSy4H-EJnuqCH_jHZR_ZhKs-4z0SUah4-Z4hz_-NxH6Db3yjdM</recordid><startdate>20220307</startdate><enddate>20220307</enddate><creator>Araújo, Natália</creator><creator>Costa, Adriana</creator><creator>Lopes, Catarina</creator><creator>Lopes-Conceição, Luisa</creator><creator>Ferreira, Augusto</creator><creator>Carneiro, Filipa</creator><creator>Oliveira, Jorge</creator><creator>Morais, Samantha</creator><creator>Pacheco-Figueiredo, Luís</creator><creator>Ruano, Luis</creator><creator>Tedim Cruz, Vítor</creator><creator>Pereira, Susana</creator><creator>Lunet, Nuno</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-0581-3663</orcidid><orcidid>https://orcid.org/0000-0003-1870-1430</orcidid><orcidid>https://orcid.org/0000-0002-0903-494X</orcidid><orcidid>https://orcid.org/0000-0002-5333-4771</orcidid><orcidid>https://orcid.org/0000-0002-1652-8999</orcidid><orcidid>https://orcid.org/0000-0003-0186-7223</orcidid></search><sort><creationdate>20220307</creationdate><title>Prevalence of Cognitive Impairment before Prostate Cancer Treatment</title><author>Araújo, Natália ; Costa, Adriana ; Lopes, Catarina ; Lopes-Conceição, Luisa ; Ferreira, Augusto ; Carneiro, Filipa ; Oliveira, Jorge ; Morais, Samantha ; Pacheco-Figueiredo, Luís ; Ruano, Luis ; Tedim Cruz, Vítor ; Pereira, Susana ; Lunet, Nuno</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c448t-8130332900ef245b25398eaee7550bb22278a41e35fae04658e96997db24beca3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Autonomy</topic><topic>Cancer therapies</topic><topic>Cognitive ability</topic><topic>COVID-19</topic><topic>Patients</topic><topic>Prostate cancer</topic><topic>Quality of life</topic><topic>Testicular cancer</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Araújo, Natália</creatorcontrib><creatorcontrib>Costa, Adriana</creatorcontrib><creatorcontrib>Lopes, Catarina</creatorcontrib><creatorcontrib>Lopes-Conceição, Luisa</creatorcontrib><creatorcontrib>Ferreira, Augusto</creatorcontrib><creatorcontrib>Carneiro, Filipa</creatorcontrib><creatorcontrib>Oliveira, Jorge</creatorcontrib><creatorcontrib>Morais, Samantha</creatorcontrib><creatorcontrib>Pacheco-Figueiredo, Luís</creatorcontrib><creatorcontrib>Ruano, Luis</creatorcontrib><creatorcontrib>Tedim Cruz, Vítor</creatorcontrib><creatorcontrib>Pereira, Susana</creatorcontrib><creatorcontrib>Lunet, Nuno</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Araújo, Natália</au><au>Costa, Adriana</au><au>Lopes, Catarina</au><au>Lopes-Conceição, Luisa</au><au>Ferreira, Augusto</au><au>Carneiro, Filipa</au><au>Oliveira, Jorge</au><au>Morais, Samantha</au><au>Pacheco-Figueiredo, Luís</au><au>Ruano, Luis</au><au>Tedim Cruz, Vítor</au><au>Pereira, Susana</au><au>Lunet, Nuno</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prevalence of Cognitive Impairment before Prostate Cancer Treatment</atitle><jtitle>Cancers</jtitle><addtitle>Cancers (Basel)</addtitle><date>2022-03-07</date><risdate>2022</risdate><volume>14</volume><issue>5</issue><spage>1355</spage><pages>1355-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>Cognitive impairment is common among patients with different types of cancer, even before cancer treatment, but no data were reported among patients with prostate cancer (PCa), who may be at high risk due to advanced age. This study aims to estimate the prevalence of cognitive impairment before PCa treatment. Between February 2018 and April 2021, the NEON-PC cohort recruited 605 patients with PCa proposed for treatment at the Portuguese Institute of Oncology of Porto. The Montreal Cognitive Assessment (MoCA) was used to assess cognitive performance. Participants with a MoCA < 1.5 standard deviations (SD) of age- and education-specific normative values were considered to have probable cognitive impairment (PCI) and were referred for a comprehensive neuropsychological assessment. Data from the population-based cohort EPIPorto (n = 351 men aged ≥40 years, evaluated in 2013−2015) were used for comparison. The prevalence of PCI was 17.4% in EPIPorto and 14.7% in NEON-PC (age- and education-adjusted odds ratio: 0.82, 95%CI: 0.58,1.18). Neuropsychological assessment was performed in 63 patients with PCa: 54.0% had cognitive impairment. These results suggest that the impact of PCa on cognitive performance could be negligible in the short term, contrary to what other studies have reported regarding other types of cancer.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>35267663</pmid><doi>10.3390/cancers14051355</doi><orcidid>https://orcid.org/0000-0002-0581-3663</orcidid><orcidid>https://orcid.org/0000-0003-1870-1430</orcidid><orcidid>https://orcid.org/0000-0002-0903-494X</orcidid><orcidid>https://orcid.org/0000-0002-5333-4771</orcidid><orcidid>https://orcid.org/0000-0002-1652-8999</orcidid><orcidid>https://orcid.org/0000-0003-0186-7223</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6694 |
| ispartof | Cancers, 2022-03, Vol.14 (5), p.1355 |
| issn | 2072-6694 2072-6694 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8909497 |
| source | MDPI - Multidisciplinary Digital Publishing Institute; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; PubMed Central Open Access |
| subjects | Autonomy Cancer therapies Cognitive ability COVID-19 Patients Prostate cancer Quality of life Testicular cancer Tumors |
| title | Prevalence of Cognitive Impairment before Prostate Cancer Treatment |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T01%3A31%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prevalence%20of%20Cognitive%20Impairment%20before%20Prostate%20Cancer%20Treatment&rft.jtitle=Cancers&rft.au=Ara%C3%BAjo,%20Nat%C3%A1lia&rft.date=2022-03-07&rft.volume=14&rft.issue=5&rft.spage=1355&rft.pages=1355-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers14051355&rft_dat=%3Cproquest_pubme%3E2638724847%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2637613425&rft_id=info:pmid/35267663&rfr_iscdi=true |